MMV & TDR anniversary symposium
Malaria prevention: A trilogy of tools to accelerate to zero deaths (Room 395/396: Friday, 15 November at 7:00–8:45 AM)
An in-person symposium sponsored by MMV and TDR to celebrate our 25th and 50th anniversaries.
Moderator: John Reeder, Special Programme for Research and Training in Tropical Diseases,
Introductory: Daniel Ngamije, WHO Global Malaria Programme, Switzerland and George Jagoe, MMV, Switzerland
- The development and rollout of the R21 vaccine and Oxford University's pipeline of vaccines: Adrian Hill, Jenner Institute, UK
- Science behind the current vaccines, the impact of those currently in use and what’s coming down the pipeline in terms of next-gen vaccines: Ashley Birkett, PATH, USA
- Preventive medicines: Cristina Donini, MMV, Switzerland
- Optimizing delivery and uptake of seasonal malaria chemoprevention and malaria vaccines: Fatimata Bintou Sall, University Iba Der Thiam Thies, Senegal
- Vector control: Justin McBeath, Innovative Vector Control Consortium, UK
- The country perspective on integration of prevention tools: Keziah Malm, National Malaria Elimination Programme, Ghana
- Gender-sensitive approaches to malaria prevention: Margaret Gyapong, Institute of Health Research at the University of Health and Allied Sciences, Ghana
- Implementation research for malaria prevention tools: Seydou Doumbia, University of Sciences, Techniques, and Technology of Bamako, Mali
Breakfast will be served from 7:00 AM
*This sponsored symposium is sponsored by MMV and TDR and is held in conjunction with the ASTMH annual meeting.
MMV & partner symposia
Ganaplacide (KAF156): a next-generation, non-artemisinin, for the treatment of P. falciparum malaria (Symposium 89 | Room 391/392: Friday, 15 November at 1:45–3:30 PM)
Chair: Abdoulaye Djimde, Malaria Research and Training Center, Mali
Co-chair: Martin Peter Grobusch, Academic Medical Center, Netherlands
- Overview of current P. falciparum malaria treatment options: Issaka Sagara, Malaria Research and Training Center, Mali
- Capacity building and methods for assessment of transmission blocking activities of the new non-artemisinin-based combination therapy (KAF156) in a Phase 3 multi-country study: Rella Zoleko Manego, Centre de Recherches Médicales de Lambaréné (CERMEL), Gabon
- Methods to assess P. falciparum dynamics of selection of drug resistance markers of a new a non-artemisinin-based combination therapy (KAF156): Colin Sutherland, London School of Hygiene & Tropical Medicine, UK
- Results of the KALUMI study: effect of food on exposure of ganaplacide-lumefantrine SDF combination. Early indicators of transmission blocking and effect in K13 mutated parasites: Caroline Boulton, Novartis, Switzerland
Implementing perennial malaria chemoprevention (PMC) across Africa: Converging to consensus? (Symposium 116 | Room 391/392: Saturday, 16 November at 8:00–9:30 AM)
Chair: Dorothy Achu, WHO Regional Office for Africa, Republic of the Congo
Co-chair: Junior Voundi Voundi, National Malaria Control Programme, Cameroon
- Pioneering PMC in Sierra Leone: Augustin Fombah, Barcelona Institute of Global Health, Spain
- Interim findings from the Plus Project evaluations in Benin, Cameroon, Cote d’Ivoire and Mozambique: Charlotte Eddis, Population Services International, USA
- Acceptability of PMC by caregivers and health workers: Evidence from the DRC: Eric Mukomena, National Malaria Control Programme, DRC
- PMC data management and reporting: The Nigerian example: Godwin Ntadom, National Malaria Elimination Programme, Nigeria
- Rolling out PMC and the malaria vaccine concomitantly: Experience from Soa in Cameroon: Junior Voundi Voundi, National Malaria Control Programme, Cameroon
Scaling the optimal use of multiple ACTs to prevent antimalarial drug resistance: Progress and challenges (Symposium 189 | Room 391/392: Sunday, 17 November at 11:30 AM – 1:15 PM)
Chair: Rima Shretta, Jhpiego, USA
Co-chair: Estee Torok, Cambridge University, UK
- Overview of drug resistance and the need for innovative treatment strategies: Rima Shretta, Jhpiego, USA
- Approaches to slowing down the current circulating Kelch13 variants in Central and Eastern Africa: Evidence on the effectiveness of multiple first-line treatments (MFT) using modelling: Maciej Boni, Temple University, USA
- From adoption to implementation of a policy of MFT in Rwanda: Aimable Mbituyumuremyi, Malaria Programme Rwanda
- Implementation research to inform the MFT strategy in Nigeria: Olugbenga Mokuolu, University of Ilorin, Nigeria
- Global efforts to diversify the use of ACTs: Supply challenges: André-Marie Tchouatieu, MMV, Switzerland
Oral presentations & posters
Oral presentation 7604 | Anna Maria van Eijk, Liverpool School of Tropical Medicine, UK: The impact of first-trimester P. falciparum malaria infections on maternal, pregnancy and infant outcomes in sub-Saharan Africa: a systematic review and individual participant data meta-analysis (Room 393/394: Friday, 15 November at 3:15 PM)
Oral presentation 6830 | Daniela Montero Salas, Novartis, Switzerland: Improving antimalarial drug efficacy assessment: Comparative analysis of length polymorphic markers and classification algorithms in two Phase 2 clinical trials (Room 391/392: Thursday, November 14 at 5:45 PM)
Poster session A: Thursday, 14 November at 12:00 PM (Hall I-1)
Poster 6356 | Bridget Barber, QIMR Berghofer, Australia: A Phase 1b study to characterize the safety and pharmacokinetic/pharmacodynamic relationship of MMV367 (GSK701) in adult participants experimentally infected with blood stage P. falciparum
Poster 6370 | Manash Shrestha, MMV: A scoping review of patient adherence to antimalarial drugs
Poster LB-9103 | Issaka Sagara, Malaria Research and Training Center, Mali: KALUMI – An adaptive run-in cohort of a Phase 2 study to evaluate food-effect of the novel antimalarial drug ganaplacide-lumefantrine in adolescent patients
Poster session B: Friday, 15 November at 12:00 PM (Hall I-1)
Poster LB-9278 | Prayuth Sudathip, Ministry of Public Health, Thailand: Operational feasibility of P. vivax radical cure after G6PD testing in Thailand
Poster LB-9258 | Florence Milando, Ifakara Health Institute, Tanzania: A Phase 1 study to evaluate the relative bioavailability and food effect of a new piperaquine oral dispersible formulation run at the Phase 1 unit in Bagamoyo, Tanzania
Poster LB-9259 | Juliether Tiago Ernest, Ifakara Health Institute, Tanzania: Palatability of a novel child-friendly piperaquine phosphate granule formulation for chemoprevention therapies of malaria in healthy adult participants
Poster LB-9228 | Preetam Gandhi, Novartis, Switzerland: Symptom profile of infants and neonates <5 kg body weight diagnosed with P. falciparum malaria and enrolled in the Phase 2/3 CALINA study
Poster session C: Saturday, 16 November at 11:00 AM (Hall I-1)
Poster 7899 | Salome Muchiri, Clinton Health Access Initiative, Inc., Kenya: Forecasting volumes of artemisinin combination therapies under various antimalarial resistance scenarios and multiple first-line therapy strategies in sub-Saharan Africa
Poster LB-9409 | Preetam Gandhi, Novartis, Switzerland: Pharmacokinetics, safety and efficacy of a new formulation of artemether-lumefantrine in the treatment of acute uncomplicated P. falciparum malaria in neonates/infants <5 kg body weight: Primary results from the CALINA study
Poster LB-9425 | Issaka Sagara, Malaria Research and Training Center, Mali: KALUMI – A Phase II study to evaluate the efficacy, safety and tolerability of the novel anti-malarial drug ganaplacide-lumefantrine in paediatric patients
Other events
Perennial malaria chemoprevention community of practice: panel discussion on the co-implementation of perennial malaria chemoprevention (IPTi) and the malaria vaccine (Hilton Riverside, Magazine Room, 3rd floor: Thursday, 14 November at 12:15–2:00 PM | Lunch will be provided)
Chair: André-Marie Tchouatieu, MMV, Switzerland
- RTS,S introduced in Cameroon in January 2024, implemented alongside routine PMC in a number of districts and pilot (Plus Project) PMC in one district: Junior Voundi Voundi, National Malaria Control Programme, Cameroon
- RTS,S introduced in Sierra Leone in April 2024, implemented alongside routine PMC: Abdul-Mac Falama, National Malaria Control Programme, Sierra Leone
- R21 introduced in Côte d'Ivoire in July 2024, implemented alongside PMC pilot (Plus Project) in one district: Serge-Brice Assi, National Malaria Control Programme, Côte d'Ivoire
- RTS,S introduced in Benin in August 2024, implemented alongside PMC pilot (Plus Project) in two districts: Julien Aissan, National Malaria Control Programme, Benin
Presentations followed by a panel discussion moderated by André-Marie Tchouatieu, MMV, Switzerland
Jhpiego & Maisha Meds side event: Financing private sector innovations in the era of antimalarial resistance (Hilton Riverside, Quarterdeck AB: Friday, 15 November at 2:00–5:00 PM)
- Opening remarks and background on policy options and economic considerations: Rima Shretta, Jhpiego, USA and Jimmy Opigo, national Malaria Control Programme, Uganda
- Panel on policy options under consideration: moderated by James Tibenderana, Malaria Consortium, UK with Jimmy Opigo, National Malaria Control Programme, Uganda; Jessica Vernon, Maisha Meds, USA; Rima Shretta, Jhpiego, USA; and Scott Filler, The Global Fund, Switzerland
- Discussion on innovations and hot topics: led by Jessica Vernon, Maisha Meds, USA with George Jagoe, MMV, Switzerland; and Kibor Keitany, National Malaria Control Programme, Kenya.
- Discussion on financing solutions: led by Abigail Pratt, Bill & Melinda Gates Foundation, USA with Kara Hanson, London School of Hygiene & Tropical Medicine, UK; Jessica Cohen, Harvard T. H. Chan School of Public Health, USA (alternate); Soji Adeyi, Resilient Health Systems, USA; and Onoriode Ezire, World Bank, Nigeria (alternate)
- Discussion on the path forward: led by James Tibenderana, Malaria Consortium, UK with David Walton, USAID PMI, USA; Scott Filler, The Global Fund, Switzerland (alternate); Samwel Lazaro, National Malaria Control Programme, Tanzania: and Kibor Keitany, National Malaria Control Programme, Kenya (alternate)
MMV's exhibitor booth
Visit our booth (309) in the exhibit hall to learn about MMV's 2024–2030 strategy. Launched in parallel with MMV's 25th anniversary, our strategic plan focuses on developing and expanding access to effective medicines to cure and protect vulnerable and underserved populations, accelerate malaria elimination efforts and enhance global health security.